Erratum: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (10.1016/j.cell.2017.08.027));Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Cell

Volumn 170, Issue 6, 2017, Pages 1109-1119.e10

  Ribas, Antoni ^a   Dummer, Reinhard ^b   Puzanov, Igor ^c   VanderWalde, Ari ^d   Andtbacka, Robert H I ^e   Michielin, Olivier ^f   Olszanski, Anthony J ^g   Malvehy, Josep ^h   Cebon, Jonathan ⁱ   Fernandez, Eugenio ^j   Kirkwood, John M ^k   Gajewski, Thomas F ^l   Chen, Lisa ^m   Gorski, Kevin S ^m   Anderson, Abraham A ^m   Diede, Scott J ⁿ   Lassman, Michael E ⁿ   Gansert, Jennifer ^m   Hodi, F Stephen ^o   Long, Georgina V ^p  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d West Clinic   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g FOX CHASE CANCER CENTER   (United States)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^j GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^k UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^l UNIVERSITY OF CHICAGO   (United States)

^m AMGEN INC   (United States)

ⁿ MERCK RESEARCH LABORATORIES   (United States)

^o DANA FARBER CANCER INSTITUTE   (United States)

^p UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

anti PD 1; biomarkers; cytotixic; interferon gamma; melanoma; oncolytic immunotherapy; oncolytic viruses; pembrolizumab; T lymphocytes; talimogene laherparepvec; tumor; tumor microenvironment

Indexed keywords

GAMMA INTERFERON; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TALIMOGENE LAHERPAREPVEC; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; AUTOIMMUNE HEPATITIS; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; CYTOTOXIC T LYMPHOCYTE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GENE EXPRESSION; HUMAN; MALE; MELANOMA; MULTICENTER STUDY; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; SINGLE BLIND PROCEDURE; TUMOR MICROENVIRONMENT; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; GENETICS; HERPESVIRIDAE; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY;

ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; HERPESVIRIDAE; HUMANS; IMMUNOTHERAPY; MELANOMA; ONCOLYTIC VIROTHERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR MICROENVIRONMENT;

EID: 85028829596     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2018.07.035     Document Type: Erratum

References (25)

1. Andtbacka, R.H., Kaufman, H.L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K.A., Spitler, L.E., Puzanov, I., Agarwala, S.S., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33 (2015), 2780–2788.
2. Andtbacka, R.H., Ross, M., Puzanov, I., Milhem, M., Collichio, F., Delman, K.A., Amatruda, T., Zager, J.S., Cranmer, L., Hsueh, E., et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann. Surg. Oncol. 23 (2016), 4169–4177.
3. Chen, P.L., Roh, W., Reuben, A., Cooper, Z.A., Spencer, C.N., Prieto, P.A., Miller, J.P., Bassett, R.L., Gopalakrishnan, V., Wani, K., et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6 (2016), 827–837.
4. Chesney, J., Collichio, F., Andtbacka, R.H., Puzanov, I., Glaspy, J.A., Milhem, M., Hamid, O., Cranmer, L., Saenger, Y., Ross, M., et al. Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB- IV melanoma. Ann. Oncol., 27, 2016, 10.1093/annonc/mdw379.04.
5. Chesney, J., Puzanov, I., Ross, M., Collichio, F., Milhem, M., Chen, L., Kim, J.H., Garbe, C., Hauschild, A., Andtbacka, R.H.I., Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma. J. Clin. Oncol., 35, 2017 9509–9509.
6. Daud, A.I., Wolchok, J.D., Robert, C., Hwu, W.J., Weber, J.S., Ribas, A., Hodi, F.S., Joshua, A.M., Kefford, R., Hersey, P., et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J. Clin. Oncol. 34 (2016), 4102–4109.
7. Gerdes, M.J., Sevinsky, C.J., Sood, A., Adak, S., Bello, M.O., Bordwell, A., Can, A., Corwin, A., Dinn, S., Filkins, R.J., et al. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc. Natl. Acad. Sci. USA 110 (2013), 11982–11987.
8. Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., McDermott, D.F., Powderly, J.D., Gettinger, S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
9. Hoffner, B., Iodice, G.M., Gasal, E., Administration and handling of talimogene laherparepvec: an intralesional oncolytic immunotherapy for melanoma. Oncol. Nurs. Forum 43 (2016), 219–226.
10. Kaufman, H.L., Kim, D.W., DeRaffele, G., Mitcham, J., Coffin, R.S., Kim-Schulze, S., Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 17 (2010), 718–730.
11. Liu, B.L., Robinson, M., Han, Z.Q., Branston, R.H., English, C., Reay, P., McGrath, Y., Thomas, S.K., Thornton, M., Bullock, P., et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10 (2003), 292–303.
12. mGM-CSF) generates systemic anti-tumor immune responses enhanced by cytotoxic T-lymphocyte-associated protein blockade. Clin. Cancer Res., 2017, 10.1158/1078-0432.CCR-17-0681 Published online July 13, 2017.
13. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264.
14. Postow, M.A., Callahan, M.K., Wolchok, J.D., Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33 (2015), 1974–1982.
15. Puzanov, I., Milhem, M.M., Minor, D., Hamid, O., Li, A., Chen, L., Chastain, M., Gorski, K.S., Anderson, A., Chou, J., et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J. Clin. Oncol. 34 (2016), 2619–2626.
16. Ribas, A., Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 5 (2015), 915–919.
17. Ribas, A., Robert, C., Hodi, F.S., Wolchok, J.D., Joshua, A.M., Hwu, W.J., Weber, J.S., Zarour, H.M., Kefford, R., Loboda, A., et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J. Clin. Oncol., 33, 2015, 3001.
18. Ribas, A., Hamid, O., Daud, A., Hodi, F.S., Wolchok, J.D., Kefford, R., Joshua, A.M., Patnaik, A., Hwu, W.J., Weber, J.S., et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315 (2016), 1600–1609.
19. Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J.C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372 (2015), 320–330.
20. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., et al., KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372 (2015), 2521–2532.
21. Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
22. Spranger, S., Spaapen, R.M., Zha, Y., Williams, J., Meng, Y., Ha, T.T., Gajewski, T.F., Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med., 5, 2013, 200ra116.
23. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
24. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
25. Wolchok, J.D., Hoos, A., O'Day, S., Weber, J.S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15 (2009), 7412–7420.